Choose Your Country or Region

Aliskiren Hemifumarate

Name: Aliskiren Hemifumarate
Brand: Selleck Chemicals
SKU: S2199
Rating: 5 (3 reviews)

Synonyms: CGP 60536 hemifumarate, CGP60536B hemifumarate, SPP 100 hemifumarate

Catalog No.S2199 Purity:99.97%

Aliskiren hemifumarate(CGP 60536 hemifumarate, CGP60536B hemifumarate, SPP 100 hemifumarate) is a direct renin inhibitor with IC50 of 1.5 nM.

Aliskiren Hemifumarate Chemical Structure

CAS No. 173334-58-2

Purity & Quality Control

Batch: Purity: 99.97%

99.97

Aliskiren Hemifumarate Related Products

Related Targets	ACE Renin	Click to Expand
Related Products	Temocapril HCl	Click to Expand
Related Compound Libraries	FDA-approved Drug Library Natural Product Library Bioactive Compound Library-I Exosome Secretion Related Compound Library Human Hormone Related Compound Library	Click to Expand

Signaling Pathway

RAAS Signaling Pathway

Biological Activity

Description

Aliskiren hemifumarate(CGP 60536 hemifumarate, CGP60536B hemifumarate, SPP 100 hemifumarate) is a direct renin inhibitor with IC50 of 1.5 nM.

Targets

Renin ^[1]

1.5 nM

In vitro
In vitro	Aliskiren hemifumarate appears to bind to both the hydrophobic S1/S3-binding pocket and to a large, distinct subpocket that extends from the S3-binding site towards the hydrophobic core of renin. Oral bioavailability of Aliskiren hemifumarate is 2.4% in rats, 16% in marmosets and about 2.5% in humans. ^[2]

In Vivo
In vivo	Aliskiren hemifumarate (< 10 mg/kg, oral) inhibits plasma renin activity and lowers blood pressure in sodium-depleted marmosets. ^[3] Once-daily oral treatment with Aliskiren hemifumarate lowers blood pressure effectively, with a safety and tolerability profile, in patients with mild-to-moderate hypertension. ^[4]

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT04432350	Withdrawn	COVID\|Drug Effect\|Drug Interaction\|Risk Reduction	Tabula Rasa HealthCare	June 12 2020	--
NCT01570686	Completed	Hypertension	Novartis Pharmaceuticals\|Novartis	April 2012	Phase 4
NCT01519635	Completed	Hypertension	Centre Hospitalier Universitaire Vaudois	October 2011	Phase 4
NCT01235910	Terminated	Hypertension\|Cardiac Transplantation	University of Colorado Denver\|American Heart Association	May 2011	Phase 4

References

+ Expand

Chemical Information & Solubility

Molecular Weight	609.83	Formula	C₃₀H₅₃N₃O₆.1/2C₄H₄O₄
CAS No.	173334-58-2	SDF	Download Aliskiren Hemifumarate SDF
Smiles	CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N.CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N.C(=CC(=O)O)C(=O)O
Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years-20°Cpowder		1 month-20°Cin solvent

In vitro
Batch:

DMSO : 122 mg/mL ( (200.05 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 122 mg/mL

Ethanol : 122 mg/mL

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):